Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

EVMN vs PROK: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EVMN Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 3–4 Matrix Metrics)

EVMN Overall Winner 6-Pillar Tally: EVMN 3 – 1 PROK (2 Tie) Matrix Metrics: EVMN 3 – 4 PROK

As of Nov 16, 2026, Evommune, Inc. (EVMN) is the stronger overall head-to-head candidate over ProKidney Corp. Class A (PROK) in the Tradestie Institutional Equity Comparison Engine, winning 3–4 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). EVMN carries a Unified Composite Score of 30.0/100 (SELL) at $7.10 (N/M Forward P/E, 0.0% operating margin), whereas PROK carries 54.0/100 (HOLD) at $1.04 (N/M Forward P/E, -24871.4% operating margin).

  • Composite vs. Pillar Nuance: While PROK currently prints a higher short-term Unified Composite Score (54.0/100 HOLD vs. EVMN 30.0/100 SELL), EVMN captures the overall institutional head-to-head verdict (3–4 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -24871.4% operating margin) and revenue trajectory (+0.0% vs. -19.8% YoY).
  • Technical & Structure Timing Caution: EVMN trades in a Neutral technical trend (SURGE options phase, RSI 52.2); meanwhile PROK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EVMN vs PROK
EVMN US Equity Head-to-Head Winner
Evommune, Inc.
Pharmaceutical Preparations
$7.10
-6.95% 1D
Market Cap $315.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.05β · 118% Vol
Unified Composite Score
30.0 / 100 SELL
Tech 50.0 Fund 35.0 Flow 69.0 Mom 44.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 52.2 · SMA20: $6.45 · SMA50: $7.47
PROK NASDAQ
ProKidney Corp. Class A Ordinary Shares
Biological Products, (No Disgnostic Substances)
$1.04
-0.48% 1D
Market Cap $417.2M
TTM Revenue $775,000
Forward P/E N/M
Beta / 30D Vol 1.68β · 92% Vol
Unified Composite Score
54.0 / 100 HOLD
Tech 33.0 Fund 65.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.7%), weak momentum, RSI 33
RSI-14: 32.5 · SMA20: $1.25 · SMA50: $1.51

6-Pillar Scorecard Institutional Category Breakdown (EVMN 3 – 1 PROK)

Columns: Metric · EVMN · PROK
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale PROK
Revenue Growth (YoY) +0.0% -19.8%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $775,000
Market Cap $315.5M $417.2M
3. Profitability & Quality EVMN
Gross Margin N/A 100.0%
Operating Margin 0.0% -24871.4%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -69.5% -73.4%
4. Balance Sheet & Cash Flow EVMN
Cash Generation (TTM) -$75M -$160M
Cash Flow Margin N/A N/A
Net Cash / Leverage $52M Net Cash $71M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EVMN
Options Structure Phase SURGE BREAKDOWN
Current IV / %ile 209.0% (53rd %ile) 446.3% (51st %ile)
Put/Call OI Skew N/A 0.83x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Neutral ACCUMULATION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EVMN (3) vs PROK (4)
Institutional Metric EVMN PROK Criterion Row Edge
Market Capitalization
Scale
$315.5M $417.2M Larger Scale PROK
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -19.8% Higher Growth EVMN
Operating Margin (TTM)
Profitability
0.0% -24871.4% Higher Margin EVMN
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-69.5% -73.4% Higher ROE EVMN
52-Week Range Position
Momentum
8% ($5–$33) 10% ($1–$3) Stronger Trend PROK
Beta / 30D Volatility
Risk Regime
1.05β · 118% Vol 1.68β · 92% Vol Lower Realized Risk PROK
Unified Institutional Score
Composite Signal
30.0 / 100 (SELL) 54.0 / 100 (HOLD) Higher Composite PROK
Trailing 12M Revenue (USD)
Operating Scale
N/A $775,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$75M ($52M Net Cash) -$160M ($71M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EVMN +59.13 pp
EVMN: +37.33% · PROK: -21.8%
3M Horizon PROK +25.43 pp
EVMN: -50.07% · PROK: -24.64%
6M Horizon PROK +32.17 pp
EVMN: -67.57% · PROK: -35.4%
1Y Horizon PROK +6.64 pp
EVMN: -61.03% · PROK: -54.39%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period EVMN Revenue PROK Revenue EVMN Op. Margin PROK Op. Margin Margin Leader
FY2024 $10M $0M -1000.2% -241678.9% EVMN
FY2025 $10M $0M -623.6% -18477.8% EVMN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EVMN SURGE
5d in phase · OBV ACCUMULATION
Current IV 209.0%
IV Percentile 53rd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact EVMN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PROK BREAKDOWN
50d in phase · OBV ACCUMULATION
Current IV 446.3%
IV Percentile 51st %ile
Put/Call OI Skew 0.83x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact PROK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EVMN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $315.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PROK Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $417.2M market capitalization and -24871.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ EVMN vs PROK Key Questions & Quantitative Answers

As of Nov 16, 2026, Evommune, Inc. (EVMN) is the stronger overall head-to-head candidate over ProKidney Corp. Class A (PROK) in the Tradestie Institutional Equity Comparison Engine, winning 3–4 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). EVMN carries a Unified Composite Score of 30.0/100 (SELL) at $7.10 (N/M Forward P/E, 0.0% operating margin), whereas PROK carries 54.0/100 (HOLD) at $1.04 (N/M Forward P/E, -24871.4% operating margin). Composite vs. Pillar Nuance: While PROK currently prints a higher short-term Unified Composite Score (54.0/100 HOLD vs. EVMN 30.0/100 SELL), EVMN captures the overall institutional head-to-head verdict (3–4 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -24871.4% operating margin) and revenue trajectory (+0.0% vs. -19.8% YoY). Technical & Structure Timing Caution: EVMN trades in a Neutral technical trend (SURGE options phase, RSI 52.2); meanwhile PROK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PROK leads the Growth & Scale pillar: EVMN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with PROK at -19.8% YoY revenue growth and +0.0% YoY earnings growth on $775,000 TTM revenue (100.0% gross margin, -24871.4% operating margin). Across the 2-period historical trajectory (FY2024 to FY2025), EVMN cumulative revenue shifted +0.0% while PROK shifted N/A. In operating R&D and SG&A reinvestment, EVMN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PROK.

EVMN and PROK trade at balanced relative valuation multiples. EVMN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas PROK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EVMN (-69.5% ROE) versus PROK (-73.4% ROE) capital efficiency.

In options market volatility and institutional positioning, EVMN carries 209.0% implied volatility (53rd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (1.05β · 118% Vol realized risk). By comparison, PROK carries 446.3% implied volatility (51st %ile, Balanced (25th–60th %ile)), a 0.83x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.68β · 92% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.